dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Sissetulev kiriAvalik

Kirja edastamine

Sotsiaalministeerium · 12. aprill 2019
Viit
1.4-2/1084-1
Registreeritud
12. aprill 2019
Dokumendi liik
Sissetulev kiri
Adressaat
Eesti Vabariigi Alaline Esindus EL juures
Saabumis/saatmisviis
e-post
Funktsioon
1.4 EL otsustusprotsess ja rahvusvaheline koostöö
Sari
1.4-2 Rahvusvahelise koostöö korraldamisega seotud kirjavahetus (Arhiiviväärtuslik)
Toimik
1.4-2/2019
Vastutaja
Helen Berk (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Terviseala asekantsleri vastutusvaldkond, Ravimiosakond)

Failid

  • 📎489_Edastamismeil.msg422 KB
  • 📎489.pdf351 KB
  • 📎E-kiri.pdf116 KB

Sisu (failidest)

Saatja: [email protected] <[email protected]> Saaja: [email protected] Teema: Ares(2019)2553091_Referral under Article 31 of Directive 2001/83/EC – High concentration estradiol containing medicinal products for topical use – Commission Implementing Decision of 19 August 2014 C(2014)6030 Our reference: Ares(2019)2553091 Dear Sirs/Madams, Please find attached a letter on the above mentioned subject. Kind regards, Unit “Medicines: policy, authorisation and monitoring“ [logo-ce-horizontal-en-quadri-jpg24] European Commission DG Health and Food Safety _____________ This message represents solely the views of its author and can not be regarded as the official position of the Commission. It is intended solely for the person to whom it is addressed and may contain confidential information. If you have received this message in error, please notify me as soon as possible. Saatja: Webdesktop <[email protected]> Saadetud: 11.04.2019 18:10 Adressaat: SM Info <[email protected]>; Elen Ohov <[email protected]>; info ravimiamet ee <[email protected]>; Kristin Raudsepp <[email protected]> Koopia: <[email protected]> Teema: Webdesktop: Kiri nr 10.2-12.T/489 / Referral under Article 31 of Directive 2001/83/EC (uue hindamismenetluse algatamine) Manused: 489.pdf; 489_Edastamismeil.msg Tere Edastan Euroopa Komisjoni kirja. Reg. number: 10.2-12.T/489 Reg. kuupäev: 11.04.2019 Sisu: Referral under Article 31 of Directive 2001/83/EC – High concentration estradiol containing medicinal products for topical use – Commission Implementing Decision of 19 August 2014 C(2014)6030 – Judgement of the European Court of Justice in case C-680/16P of 27 March 2019 - New referral procedure Heade soovidega Tiiu Noobel sekretär EV AEEL juures Ref. Ares(2019)2553091 - 11/04/2019 EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems, medical products and innovation Medicines: policy, authorisation and monitoring Head of Unit Brussels, sante.ddg1.b5/FS/an(2019)2835813 By email only Dear Sirs/Madams, Subject: Referral under Article 31 of Directive 2001/83/EC – High concentration estradiol containing medicinal products for topical use – Commission Implementing Decision of 19 August 2014 C(2014)6030 – Judgement of the European Court of Justice in case C-680/16P of 27 March 2019 With this letter we would like to inform you that Commission Implementing Decision C(2014)6030 final of 19 August 2014 has been partially annulled by the judgement of the European Court of Justice of 27 March 2019. 1. BACKGROUND By its implementing decision of 19 August 2014, the Commission completed a Union interest referral under Article 31 on high-concentration estradiol containing products. Based on the scientific opinion of the European Medicines Agency it was found that the authorised use of the product should be restricted and product information should be updated to better reflect the product’s risk. In view of those changes to the benefit-risk balance, Member States were requested to amend the national marketing authorisations concerned. Two of the marketing authorisation holders concerned brought the Commission to court and requested the annulment of the Commission decision. By its judgment of 27 March 2019, the Court of Justice decided to partially annul the Commission decision. According to the Court, taking into account the particular circumstances of the case, the handling of the review of the concerned products by the responsible committee of the European Medicines Agency had not ensured sufficient guarantees to exclude any legitimate doubts as to compliance with the obligation of impartiality as enshrined in Article 41 of the Charter (case C-680/16P). Commission européenne, B-1049 Bruxelles / Europese Commissie, B-1049 Brussel - Belgium. Telephone: (32-2) 299 11 11. E-mail: [email protected] However, it is important to stress that the Court did not annul the Commission Implementing Decision in its entirety, but only: "in so far as that decision directs the Member States to comply with the requirements which it stipulated for the medicinal products, for which Dr. August Wolff GmbH & Co. KG Arzneimittel and Remedia d.o.o. hold marketing authorisation, with 0.01% estradiol by weight for topical use referenced and non-referenced in Annex I thereto, excluding the restriction that the medicinal products with 0.01% estradiol by weight for topical use referenced in that annex may still be used by vaginal application only." It follows that the annulment is limited in content and limited in scope, as it only applies to the marketing authorisations of the companies Dr. August Wolff GmbH & Co. KG Arzneimittel and Remedia d.o.o. Given that the Commission Implementing Decision was addressed to Member States, Member States are asked to review in due course the national decisions they have taken at the time to implement it. The partial annulment of the Commission Decision may directly affect the validity of those national decisions to vary the marketing authorisations concerned. Hence, the concerned Member States are required to take the necessary steps to fully implement the judgment. 2. NEXT STEPS The partial annulment of the Commission Decision leads to the invalidation of some of the restrictive measures that have been taken as the outcome of the above described review, even if the scientific assessment of the products was not put into question by the Court of Justice in its judgment. Therefore the European Commission is concerned that the identified safety risks are no longer appropriately addressed and that patients are put at a risk. As a consequence, it has launched a new referral procedure under Article 31 of Directive 2001/83/EC. Yours sincerely, [Electronically signed] p.o. Florian Schmidt Olga Solomon 2 Electronically signed on 11/04/2019 13:41 (UTC+02) in accordance with article 4.2 (Validity of electronic documents) of Commission Decision 2004/563
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel